Archive · 27 Jul 2026
Netflix Executive Sues After Firing Over Ketamine Therapy Disclosure
A former Netflix executive named Kevin Baillie is suing the company because he believes he was fired unfairly.
He had told his colleagues about a special medical treatment he was getting for his depression, which involved a drug called ketamine.
This treatment was supervised by doctors and was meant to help him feel better.
However, he thinks Netflix misunderstood and thought he was using drugs for fun, not for medical reasons.
He also says that the company investigated him unfairly and even denied him the money he was supposed to get when he left his job.
Baillie wants a jury to hear his case and to be compensated for what he has lost.
Kevin Baillie, a former Netflix executive, is suing the company for wrongful termination.
He disclosed medically supervised ketamine therapy for depression during a company retreat.
Baillie claims the disclosure led to an unfair investigation and his eventual dismissal.
He alleges that Netflix misconstrued his medical treatment as recreational drug use.
Baillie is seeking compensation for lost wages, emotional distress, and punitive damages.
- Who
- Kevin Baillie, former Netflix executive
- What
- Suing Netflix for wrongful termination after disclosing ketamine therapy
- When
- Filed in 2026
- Where
- United States
- Why
- Alleges he was fired due to disclosing medically supervised ketamine therapy
Kevin Baillie's Perspective
Netflix's Perspective
Reason for Dismissal
Kevin Baillie's Perspective
Baillie claims he was fired due to disclosing medically supervised ketamine therapy for depression, which was misconstrued as recreational drug use.
Netflix's Perspective
Netflix has not publicly responded to the allegations, so their perspective is unknown.
Workplace Environment
Kevin Baillie's Perspective
Baillie alleges that the company's investigation was unfair and that alcohol consumption was common at company events.
Netflix's Perspective
Netflix has not publicly responded to the allegations, so their perspective is unknown.
- Plaintiff
- Kevin Baillie
- Position
- Vice President and Head of Creative at Eyeline Studios
- Treatment
- Medically supervised ketamine therapy
- Reason for Treatment
- Clinical depression following the death of his mother
- Company Retreat
- January 2026 at Sendero Ranch, Northern California
- Investigation
- March 2026
- Dismissal
- April 2026
- Severance Denied
- Up to a year's worth of severance pay